Linezolid Alone and in Combination with Rifampicin Prevents Experimental Vascular Graft Infection Due to Methicillin-Resistant Staphylococcus aureus and Staphylococcus epidermidis

Saçar, Mustafa; Saçar, Suzan; Kaleli, İlknur; Önem, Gökhan; Turgut, Hüseyin; Gökşin, İbrahim; Özcan, Vefa; Inan, Bilal Kaan; Duver, Harun; Baltalarlı, Ahmet

doi:10.1016/j.jss.2006.10.003

Cited by 21 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of combination treatment with rifampin and other antistaphylococcal agents, including teicoplanin (27) and daptomycin (13), has been shown in other animal experiments where, again, tissue cages were employed. The activity of combination treatment with rifampin plus linezolid was also shown in a rat model of vascular graft infection (25).…”

Section: Discussionmentioning

confidence: 92%

Treatment with Linezolid or Vancomycin in Combination with Rifampin Is Effective in an Animal Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis

Vergidis

Rouse

Euba

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Rifampin monotherapy was compared to the combination of linezolid or vancomycin with rifampin in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) chronic foreign body osteomyelitis. MRSA was inoculated into the proximal tibia, and a titanium wire was implanted. Four weeks after infection, rats were treated intraperitoneally for 21 days with rifampin alone (n ‫؍‬ 16), linezolid plus rifampin (n ‫؍‬ 14), or vancomycin plus rifampin (n ‫؍‬ 13). Thirteen animals received no treatment. At completion of treatment, qualitative cultures of the wire and quantitative cultures of the bone (reported as median values) were performed. Quantitative cultures from the control, rifampin monotherapy, linezolid-plus-rifampin, and vancomycin-plus-rifampin groups revealed 4.54, 0.71, 0.10, and 0.50 log 10 CFU/gram of bone, respectively. The bacterial load was significantly reduced in all treatment groups compared to that in the control group. Rifampin resistance was detected in isolates from 10, 2, and 1 animal in the rifampin, linezolid-plus-rifampin, and vancomycin-plus-rifampin groups, respectively. Cultures of the removed wire revealed bacterial growth in 1 and 2 animals in the rifampin and linezolid-plus-rifampin groups, respectively, with no growth in the vancomycin-plus-rifampin group and growth from all wires in the untreated group. In conclusion, we demonstrated that combination treatment with linezolid plus rifampin or vancomycin plus rifampin is effective in an animal model of MRSA foreign body osteomyelitis in the context of retention of the infected foreign body.

show abstract

Section: Discussionmentioning

confidence: 92%

Treatment with Linezolid or Vancomycin in Combination with Rifampin Is Effective in an Animal Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis

Vergidis

Rouse

Euba

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…We chose an in vitro model because the delayed incubation of uncoated and coated prostheses presumably simulates the effect of the pretreatment on delayed contamination consistent with the clinical occurrence of early infection in the perioperative or early postoperative phase. The most frequent cause of vascular graft infection is contamination of the graft during the implantation or in the perioperative period with S. aureus and S. epidermidis as most common etiologic agents [6].…”

Section: Discussionmentioning

confidence: 99%

“…These washed samples were transferred into sterile universal containers containing 5 mL PBS. The viable adherent bacteria were released by sonification [6] on low power for 20 min. This regimen was found in prior experiments to remove all adherent bacteria without affecting their viability, an outcome which was verified using electron microscopy.…”

Section: Direct Counting Of Viable Adherent Bacteriamentioning

confidence: 99%

“…Additionally, antibiotic therapy is unable to reach a sufficient topical concentration and thus cure these infections, as the biofilm protects the embedded bacteria against antibacterial agents [4]. Preventive strategies, such as the prophylactic use of a single-shot antibiotic administration immediately prior to implantation and meticulous aseptic techniques, form the mainstay of current practice [5,6]. Furthermore, prevention of bacterial adhesion to the surface of a vascular prosthesis is of great importance.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of Early Vascular Graft Infection Using Regional Antibiotic Release

Kuehn

Graf

Mashaqi

et al. 2010

Journal of Surgical Research

View full text Add to dashboard Cite

“…There have been studies on the use of antibiotic-impregnated or antibiotic-soaked grafts, but these, as the sole source of antibiotics, are often insufficient to prevent graft infection. 16,17 Prophylactic rifampicin-soaked gelatin-impregnated grafts have failed to reduce graft infection rates at 1 month or at 2 years in a systematic review. 18 Glues have also been used as a drug carrier for antibiotics, but the release periods they offered were less than 72 hours, 19,20 which was inadequate for treatment of vascular graft infection.…”

mentioning

confidence: 99%

Sustained release of vancomycin from novel biodegradable nanofiber-loaded vascular prosthetic grafts: in vitro and in vivo study

Liu¹,

Lee²,

Wang³

et al. 2015

IJN

View full text Add to dashboard Cite

This study describes novel biodegradable, drug-eluting nanofiber-loaded vascular prosthetic grafts that provide local and sustained delivery of vancomycin to surrounding tissues. Biodegradable nanofibers were prepared by first dissolving poly(D,L)-lactide-co-glycolide and vancomycin in 1,1,1,3,3,3-hexafluoro-2-propanol. The solution was then electrospun into nanofibers onto the surface of vascular prostheses. The in vitro release rates of the pharmaceutical from the nanofiber-loaded prostheses was characterized using an elution method and a high-performance liquid chromatography assay. Experimental results indicated that the drug-eluting prosthetic grafts released high concentrations of vancomycin in vitro (well above the minimum inhibitory concentration) for more than 30 days. In addition, the in vivo release behavior of the drug-eluting grafts implanted in the subcutaneous pocket of rabbits was also documented. The drug-eluting grafts developed in this work have potential applications in assisting the treatment of vascular prosthesis infection and resisting reinfection when an infected graft is to be exchanged.

show abstract

Linezolid Alone and in Combination with Rifampicin Prevents Experimental Vascular Graft Infection Due to Methicillin-Resistant Staphylococcus aureus and Staphylococcus epidermidis

Cited by 21 publications

References 35 publications

Treatment with Linezolid or Vancomycin in Combination with Rifampin Is Effective in an Animal Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis

Treatment with Linezolid or Vancomycin in Combination with Rifampin Is Effective in an Animal Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis

Prevention of Early Vascular Graft Infection Using Regional Antibiotic Release

Sustained release of vancomycin from novel biodegradable nanofiber-loaded vascular prosthetic grafts: in vitro and in vivo study

Contact Info

Product

Resources

About